Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | HCAR1 | Q9BXC0 | 5/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2619124 | 0.85 | MAPKAPK2 (0.50) | CA12CA9PDE3BPDE3AMAPKAPK2 | |
| SCHEMBL31093789 | 0.79 | F11 (0.47) | HCAR1PDE3BPDE3AMAPKAPK2RPS6KA3 | |
| SCHEMBL4137137 | 0.79 | F11 (0.47) | HCAR1PDE3BPDE3AMAPKAPK2RPS6KA3 | |
| SCHEMBL4135759 | 0.78 | DYRK1A (0.49) | HCAR1PDE3BPDE3AMAPKAPK2RPS6KA3 | |
| SCHEMBL1378724 | 0.78 | MAPKAPK2 (0.42) | HCAR1PDE3BPDE3AMAPKAPK2RPS6KA3 | |
| SCHEMBL9980482 | 0.78 | MAPKAPK2 (0.42) | CA12CA9HCAR1PDE3BPDE3A | |
| SCHEMBL1374700 | 0.77 | MMP12 (0.47) | HCAR1PDE3BPDE3AALDH1A1CYP1A2 | |
| SCHEMBL19737587 | 0.77 | MAPT (0.40) | CA12CA9HCAR1PDE3BPDE3A | |
| SCHEMBL19751457 | 0.77 | PDE3B (0.44) | HCAR1PDE3BPDE3AMAPKAPK2RPS6KA3 | |
| SCHEMBL15829280 | 0.77 | SCN10A (0.43) | PDE3BPDE3AMAPKAPK2RPS6KA3CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024074611-A1 | PRMT5 INHIBITORS | Ryvu Therapeutics S.A. (PL) | 2024-04-11 | — | — | WO | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-20220089595-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2022-03-24 | — | — | US | disclosed |
| US-11230545-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-25 | — | — | US | disclosed |
| US-20210332045-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-10-28 | — | — | US | disclosed |
| US-20210317111-A1 | NOVEL MEDICAMENT FOR TREATING INFLAMMATORY BOWEL DISEASE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-10-14 | — | — | US | disclosed |
| US-20200055823-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2020-02-20 | — | — | US | disclosed |
| US-20190077762-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3318557-A2 | QUINOLONE COMPOUND | Otsuka Pharmaceutical Co., Ltd. (JP) | 2018-05-09 | — | — | EP | disclosed |
| US-20170362180-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-8211908-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-8211908-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-8211908-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| WO-2011149937-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-2022793-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-02-11 | — | — | EP | disclosed |
| US-7235562-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2007-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362180-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | CA12 3638/4885CA9 1916/4885HCAR1 949/4885 |
| US-20200055823-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | CA12 3638/4885CA9 1916/4885HCAR1 949/4885 |
| US-20220089595-A1 | HETEROCYCLIC COMPOUND | MALT1, SQSTM1, PPM1D | CA12 1633/4885CA9 1037/4885HCAR1 1620/4885 |
| US-11230545-B2 | Heterocyclic compound | MALT1, SQSTM1, PPM1D | CA12 1633/4885CA9 1037/4885HCAR1 1620/4885 |
| US-20210332045-A1 | HETEROCYCLIC COMPOUND | MALT1, SQSTM1, PPM1D | CA12 1633/4885CA9 1037/4885HCAR1 1620/4885 |
| US-11730720-B2 | ALK5 inhibitors | ALK, ACVR1, ACVRL1 | CA12 3199/4885CA9 2336/4885HCAR1 2074/4885 |
| US-20190077762-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | CA12 3657/4885CA9 1913/4885HCAR1 995/4885 |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, H1-4 | CA12 889/4885CA9 2191/4885HCAR1 1208/4885 |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, CXXC5 | CA12 1232/4885CA9 2402/4885HCAR1 1360/4885 |
| US-20210317111-A1 | NOVEL MEDICAMENT FOR TREATING INFLAMMATORY BOWEL DISEASE | FABP2, SLC10A2, NFKBIA | CA12 3911/4885CA9 4572/4885HCAR1 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.